COVID-19 Vaccine Training Materials available from the CDC
Find below information and resources on the COVID-19 Vaccination Program from the Defense Health Agency Immunization Healthcare Division. This information is geared toward health care personnel in the Department of Defense (DOD). This page is reviewed daily and more content is added as soon as it becomes available...
DHA-IPM 20-004: DOD Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation (June 16, 2022)
Information Paper on Novavax COVID-19 Vaccine (July 25, 2022)
Novavax COVID-19 Vaccine: Information on Fetal Cell/Fetal Tissue (July 22, 2022)
Note: Right-click and save these documents to your desktop in order to fill them out and add digital signature.
Note: The FDA-approved COMIRNATY (COVID-19 Vaccine, mRNA) and the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine under Emergency Use Authorization (EUA) have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series.
Note: The Pfizer-BioNTech vaccine for 5–11-year-olds is a new product configuration with new packaging, new preparation, and a new national drug code (NDC). The previously existing product for adults and adolescents should not be used in children younger than 12.
Note: The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a 3-dose primary series to individuals 6 months through 4 years of age.
Back to top of page
Note: The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 18 years of age and older can be used interchangeably.
Note: The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the Moderna COVID19 Vaccine authorized for Emergency Use Authorization (EUA) for individuals 12 years of age and older can be used interchangeably, when used according to their respective instructions for use.
Note: Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border is authorized to provide 0.5 mL primary series doses to individuals 6 years through 11 years of age and to provide 0.5 mL booster doses to individuals 18 years of age and older.
Note: Moderna COVID-19 Vaccine supplied in multiple-dose vials with a dark blue cap and a label with a magenta border is intended for use in individuals 6 months through 5 years of age and should not be used in individuals 6 years of age and older.
Note: The dates on the bottom of the documents are always the dates of the last updates. The documents in the links above update automatically when the FDA releases new versions.
Bullet Background Paper on Pfizer-BioNTech COVID-19 Vaccine Buffer Solution (Nov. 8, 2021)
U.S. COVID-19 Vaccine Product Information (May 26, 2022)
Transporting Vaccine for Vaccination Clinics Held at Satellite, Temporary or Off-Site Locations (Aug. 24, 2021)
Temperature Log when Transporting Vaccine at Refrigerated Temperatures (Feb. 18, 2021)
Vaccine Storage Troubleshooting Record for Temperature Excursions (August 2021)
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 (Aug. 13, 2021)
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 (Aug. 27, 2021)
The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 (Nov. 5, 2021)
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022 (July 1, 2022)
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 (Sept. 24, 2021)
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 (March 2, 2021)
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 (April 27, 2021)
A warrior care coordinator shares how she supports recovering service members, their families and caregivers.
Recommended Content:
DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101
The appearance of hyperlinks does not constitute endorsement by the Defense Health Agency of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.